Oral immune-related adverse events in patients with and without inflammatory bowel disease receiving immune checkpoint inhibitor therapy
Orale immunvermittelte unerwünschte Ereignisse bei Patient:innen mit und ohne entzündliche Darmerkrankung unter Therapie mit Immun-Checkpoint-Inhibitoren
Inflammatory Bowel Diseases · 02.11.2026
DOI: 10.1093/ibd/izag195 ↗Auf einen Blick
Bei erwachsenen Krebspatient:innen unter Immun-Checkpoint-Inhibitoren traten orale irAEs bei bestehender IBD seltener auf. Die Symptomschwere war meist ähnlich, Rezidive waren seltener.
Fragestellung
Ist bei Patient:innen mit IBD das Risiko oder die Schwere oraler immunvermittelter unerwünschter Ereignisse unter ICI-Therapie erhöht?
Methode
Retrospektive Kohortenstudie bei erwachsenen Krebspatient:innen an einem tertiären Krebszentrum von 2012 bis 2024; Abgleich von IBD-Patient:innen mit Nicht-IBD-Patient:innen 1:2 nach Alter, Geschlecht und Tumorart.
Ergebnisse
Von 450 mit ICIs behandelten Patient:innen hatten 152 eine vorbestehende IBD. Bei IBD waren orale Läsionen seltener, Xerostomie, Dysgeusie, Mukositis, Dysphagie und orale Candidiasis niedriger; Schweregrade für Mukositis, orale Schmerzen und Dysphagie ähnlich.
Schlussfolgerung der Autor:innen
Patient:innen mit IBD, die ICIs erhielten, entwickelten seltener orale irAEs als Patient:innen ohne IBD; dies könnte mit protektiven Effekten begleitender IBD-Therapien zusammenhängen.
Kernaussagen
- Orale irAEs traten bei IBD seltener auf
- Schweregrade von Mukositis, Schmerzen und Dysphagie waren ähnlich
- Rezidive und supportive Therapie waren in der IBD-Gruppe seltener
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 02.11.2026. Verfasst von Sharada Wali und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer CenterHouston, TX 77030, United States. Die Arbeit nennt 28 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) are associated with oral immune-related adverse events (irAEs). We sought to determine whether mucosal immune dysregulation in inflammatory bowel disease (IBD) predisposes patients to a higher risk or severity of these toxic effects.
Methods
This retrospective cohort study evaluated adult cancer patients treated with ICIs at a tertiary cancer center between 2012 and 2024. Patients who developed oral irAEs within 1 year of starting ICIs were stratified by IBD status; IBD patients were matched 1:2 with non-IBD patients based on age, sex, and cancer type. We retrieved clinical information from electronic health records.
Results
Of 450 patients treated with ICIs, 152 had pre-existing IBD. Patients with IBD had a longer median time to oral lesion onset. Oral mucosal toxic effects were significantly less frequent, and symptoms such as xerostomia, dysgeusia, mucositis, dysphagia, and oral candidiasis were all significantly lower in IBD patients. Severity grades for mucositis, oral pain, and dysphagia were similar between groups. Supportive care for oral irAEs was used less often in the IBD group. Hospitalizations due to oral lesions were rare, and ICI therapy was paused in similar proportions between groups. Recurrence of oral lesions was less frequent in IBD patients.
Conclusion
Patients with IBD who receive ICIs were less likely to develop oral irAEs than those without IBD, possibly due to the protective effects of concurrent IBD therapies initiated before or during ICI treatment. These results highlight the feasibility and tolerability of ICI therapy in patients with IBD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer CenterHouston, TX 77030, United States.
- Department of Internal Medicine, Baylor College of MedicineHouston, TX 77030, United States.
- Department of Internal Medicine, The University of Texas Health Science Center, Houston, TX 77030, United States.
- Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX 77555, United States.
- Department of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, United States.
- Department of Medicine, Division of Hematology-Oncology, UMass Memorial Medical Center, Worcester, MA 01605, United States.
ORCID-Profile: Mehmet Altan, Yinghong Wang
Zitieren
APA
Wali, S., Adames, S. M., Ngo, S., Gupta, T., Chatterjee, A., Rehman, A., Rizvi, M., Quirk, N., Santos, M. J. N. M., Cruz, C. C., Kim, S., Varatharajalu, K., Dougan, M. L., Mittal, K., Lei, Y. L., Altan, M., Thomas, A., & Wang, Y. (2026). Oral immune-related adverse events in patients with and without inflammatory bowel disease receiving immune checkpoint inhibitor therapy. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag195
Vancouver
Wali S, Adames SM, Ngo S, Gupta T, Chatterjee A, Rehman A, et al. Oral immune-related adverse events in patients with and without inflammatory bowel disease receiving immune checkpoint inhibitor therapy. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag195
BibTeX
@article{Wali2026,
author = {Wali, Sharada and Adames, Saltenat Moghaddam and Ngo, Sean and Gupta, Tanvi and Chatterjee, Anirudha and Rehman, Ahmed and Rizvi, Mariam and Quirk, Nina and Santos, Maria Julia Nascimento Moura and Cruz, Carolina Colli and Kim, Stephanie and Varatharajalu, Krishnavathana and Dougan, Michael L and Mittal, Kriti and Lei, Yu Leo and Altan, Mehmet and Thomas, Anusha and Wang, Yinghong},
title = {Oral immune-related adverse events in patients with and without inflammatory bowel disease receiving immune checkpoint inhibitor therapy},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izag195}
}
EUVIMED